Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, has had a new drug registration application for Luvometinib Tablets (brand name 复迈宁) accepted by China’s National Medical Products Administration and granted priority review status. The filing seeks an additional indication for treating adult patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely resected, expanding on Luvometinib’s existing approved uses in China. The priority review designation underscores the unmet medical need in this rare disease area and signals potential acceleration of the approval timeline, which could strengthen Fosun Pharma’s innovative drug portfolio and enhance its competitive position in targeted small‑molecule therapies.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical group engaged in the research, development, manufacturing and commercialization of innovative drugs and healthcare products. Through its subsidiaries, the company focuses on small-molecule innovative therapies and serves both domestic and international markets, with a growing portfolio targeting oncology and other serious diseases.
Average Trading Volume: 3,861,331
Technical Sentiment Signal: Sell
Current Market Cap: HK$74.73B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.